These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8212705)

  • 21. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction.
    Bennett JP; Landow ER; Dietrich S; Schuh LA
    Mov Disord; 1994 Jul; 9(4):409-14. PubMed ID: 7969207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
    Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A
    Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Carta A; Ryatt J; Quinn N; Jenner P; Marsden CD; Agnoli A
    Mov Disord; 1992; 7(3):249-56. PubMed ID: 1620143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience].
    Roth J; Růzicka E; Mecír P
    Cas Lek Cesk; 1994 Nov; 133(21):665-7. PubMed ID: 7805088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration.
    Clough CG; Bergmann KJ; Yahr MD
    Adv Neurol; 1984; 40():131-40. PubMed ID: 6695589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease.
    Antonini A; Odin P
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S97-100. PubMed ID: 20123567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease.
    Dewey RB; Maraganore DM; Ahlskog JE; Matsumoto JY
    Mov Disord; 1998 Sep; 13(5):782-7. PubMed ID: 9756146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset.
    Pantelatos A; Fornadi F
    Adv Neurol; 1993; 60():690-7. PubMed ID: 8420212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Apomorphine as adjuvant treatment in idiopathic Parkinson syndrome].
    Bösch MF; Ludin HP
    Schweiz Arch Neurol Psychiatr (1985); 1994; 145(5):8-13. PubMed ID: 7709189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease].
    Miranda M; Saéz D
    Rev Med Chil; 1995 Mar; 123(3):326-9. PubMed ID: 8525172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-dose L-dopa response in early Parkinson's disease: measurements with optoelectronic recording technique.
    Johnels B; Ingvarsson PE; Holmberg B; Matousek M; Steg G
    Mov Disord; 1993; 8(1):56-62. PubMed ID: 8419808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dystonia and Parkinson's disease.
    Carella F; Giovannini P; Girotti F; Testa D; Caraceni T
    Adv Neurol; 1993; 60():558-61. PubMed ID: 8420191
    [No Abstract]   [Full Text] [Related]  

  • 35. Protective effect of selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208
    [No Abstract]   [Full Text] [Related]  

  • 36. The motor response to sequential apomorphine in parkinsonian fluctuations.
    Hughes AJ; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):358-60. PubMed ID: 2056323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
    Di Rosa AE; Epifanio A; Antonini A; Stocchi F; Martino G; Di Blasi L; Tetto A; Basile G; Imbesi D; La Spina P; Di Raimondo G; Morgante L
    Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.
    van Laar T; Neef C; Danhof M; Roon KI; Roos RA
    Mov Disord; 1996 Nov; 11(6):633-8. PubMed ID: 8914088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Limited value of the apomorphine test in Parkinson disease].
    Roos RA; van Laar T; van Hilten JJ
    Ned Tijdschr Geneeskd; 1994 Jul; 138(27):1374-6. PubMed ID: 7913520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.